Walker Sands Launches AI Domain Impact Index to Advance PR Strategy and Measurement in the Generative AI Era
As Google's search dominance declines and GenAI platforms drive increasingly more traffic, the channels for reaching B2B audiences are shifting rapidly. This evolution demands a new approach to PR measurement and target media prioritization.
Because GenAI platforms rely heavily on credible third-party content, strategic media placements play a critical role in shaping brand visibility and trust in AI-assisted buyer journeys. The AI Domain Impact Index offers insight into how earned media influences GenAI search results — and ultimately, how brands appear in AI-driven decision-making workflows.
'AI is rapidly changing how people discover and engage with information, and marketers can't afford to rely on outdated assumptions about which media platforms are most influential,' said Annie Gudorf, EVP at Walker Sands. 'The AI Domain Impact Index gives brands critical insights on how to stay visible and credible by identifying the digital domains that matter most in today's landscape.'
A New Standard for Measuring Media Impact in an AI World
The AI Domain Impact Index assigns a 0–100 score to any web domain based on an evaluation of five weighted criteria: organic search, inclusion, on-page, real-time retrieval and citation appearance. Unlike traditional vanity metrics, the Impact Index connects PR outcomes to tangible visibility in AI search — giving marketers a clearer, ROI-driven view of their PR strategy's influence over time.
Importantly, scores within the Impact Index evolve over time, with GenAI models continually adjusting how they prioritize sources and media publications to optimize for LLMs. This reinforces the need for dynamic, data-informed media strategies and positions the Impact Index as a critical tool for staying ahead of shifting AI model behavior.
In an initial analysis of over 600 earned media placements from client programs, Walker Sands evaluated 292 unique media domains using the AI Domain Impact Index. The results are encouraging:
51% of placements were categorized as high impact, meaning they are highly likely to influence GenAI search responses.
44% were moderately impactful, and only 4% fell into the low-impact tier.
Notably, outlets like TechTarget, Apple Podcasts, ZDNet and ITPro ranked among the highest-impact sources, while some traditionally trusted media platforms scored lower. These findings validate that AI search visibility depends on a different set of content signals than traditional SEO and that earned media strategies must adapt accordingly.
'We've seen shifts in domain ranking in GenAI responses compared to just a few months ago, as well as media publications actively optimizing their content for better discoverability," said John Fairley, SVP Marketing Operations + SEO. 'The Impact Index gives us critical, real-time insight into these changes, allowing us to partner with our clients to maximize discoverability potential through earned media.'
Learn More
Walker Sands is among the first B2B agencies to operationalize generative AI search dynamics within PR workflows. The AI Domain Impact Index signals a bold evolution in how brands prepare for the future of search.
To explore how the AI Domain Impact Index can elevate your PR program, click here. Interested in speaking with an expert about our PR services? Reach out today.
About Walker Sands
Walker Sands is an outcome-based B2B marketing agency with expertise in strategy, content, creative, strategic communications and digital marketing. The agency helps B2B brands grow, build reputation, generate demand, drive engagement and strengthen market position. A 10-time Inc. 5000 honoree, Walker Sands is one of the fastest-growing B2B agencies in the world, proudly serving 100+ clients from offices in Chicago, Seattle and Boston. Learn more at walkersands.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
I missed Nvidia – could this be the next big US growth stock?
Let's be honest — most of us missed the boat on Nvidia (NASDAQ: NVDA). And by the time we realised just how vital graphics processing units (GPUs) would become to artificial intelligence (AI), the share price had already soared into the stratosphere. Over the past five years, the stock has climbed almost 1,600%. In the last six months alone, it's up almost 50%, adding over $1.5trn to its market value. It's now the most valuable company in the world, overtaking Microsoft and Apple in June. I have exposure to the stock through several ETFs and investment trusts, so I didn't entirely miss out on the action. But I certainly made nowhere near the gains I would have had I bought individual shares. Which makes me wonder, how did Nvidia get here, and what stock could be next? Crunching the numbers The numbers behind the hype are jaw-droppingly impressive. For the fiscal year ending January 2025, revenue reached $130bn, a staggering increase from $27bn just two years ago. Net income exploded from $4.3bn in 2022 to more than $70bn this year. And its margins are enormous — a return on equity of 115% and gross margins consistently above 70%. Yet despite the parabolic growth, I don't think it's entirely overvalued yet. In fact, I still think it's worth considering as a long-term investment. It's a world-class company with room to expand further and the global AI arms race is just getting started – with Nvidia at its core. Realistically, though, the biggest gains have already been made. Buying now means betting on continued dominance that may already be priced in, which is a risk. The stock trades at a price-to-earnings (P/E) ratio of 45 – not outrageous considering its growth, but not cheap either. So where should investors look if they want to catch the next killer growth stock before it becomes a trillion-dollar giant? Could SymphonyAI be next? One company on my radar is SymphonyAI, a private US firm reportedly preparing for a Nasdaq IPO later this year. It's not yet listed, but when it does go public, I'll be watching closely. Founded by billionaire Romesh Wadhwani, it specialises in applying AI to specific industry verticals – retail, finance, manufacturing, and healthcare. It doesn't build chips like Nvidia, but it builds the enterprise software that helps businesses harness AI to improve decision-making and productivity. Unlike many AI startups, SymphonyAI already has real revenues and customers. Its retail division serves over 1,200 brands, while its industrial arm works with giants like Nestlé and ArcelorMittal. While financials are still private, it reportedly generates hundreds of millions in annual revenue and is growing fast. If the IPO goes ahead this autumn, it could be one of the most closely watched tech listings of the year. Long-term mindset Nvidia's success was powered by timing, technology, and a growing reliance on data. It may still reward shareholders but the days of 10x returns are likely behind us. SymphonyAI might never reach Nvidia's heights but it could offer early-stage exposure to enterprise AI – the next leg of this growth story. If the valuation is right, it could turn out to be a once-in-a-decade opportunity. The post I missed Nvidia – could this be the next big US growth stock? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
38 minutes ago
- Business Insider
Tim Cook Says He's 'Open to M&A that Accelerates' Apple's AI Plans
Tech giant Apple (AAPL) is changing its strategy on artificial intelligence, with CEO Tim Cook saying that the company is now willing to spend more in order to catch up to competitors. Interestingly, this could involve building more data centers or even acquiring a larger AI company, which would be a big shift from Apple's usual practice of buying smaller firms. The move comes as Apple falls behind Microsoft (MSFT) and Google (GOOGL), which have already spent tens of billions on AI chatbots and assistants that now have hundreds of millions of users. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. So far, Apple has mainly relied on outside data centers and focused on developing its own AI technology. But progress has been slower than expected, with Siri's upgrade pushed to next year. As a result, during Apple's Q3 earnings call, Cook told analysts that while the company has acquired seven smaller firms this year, it is also open to larger deals if they help speed up Apple's AI plans. 'We're very open to M&A that accelerates our roadmap,' he said, with CFO Kevan Parekh adding that this spending will rise 'substantially,' but not at an out-of-control pace. It is worth noting that these plans come at a critical time for Apple. Indeed, its multibillion-dollar deal with Google to keep it as the iPhone's default search engine is at risk due to U.S. antitrust lawsuits. In addition, new AI startups like Perplexity are working with phone makers to challenge Google's dominance, with Bloomberg even reporting earlier this year that Apple had discussed buying Perplexity to improve its Safari browser. At the same time, Apple is preparing to spend more on data centers so it can use its own chips to process AI tasks while protecting user privacy. Is Apple a Buy or Sell Right Now? Turning to Wall Street, analysts have a Moderate Buy consensus rating on AAPL stock based on 13 Buys, 12 Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average AAPL price target of $230.97 per share implies 13.7% upside potential.
Yahoo
2 hours ago
- Yahoo
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
Tempus AI, Inc. TEM is scheduled to report second-quarter 2025 results on Aug. 8. In the last reported quarter, the company's adjusted loss of 24 cents was narrower than the Zacks Consensus Estimate of a loss of 27 cents per share. Tempus AI, which went public in June 2024, exceeded estimates in two of the trailing four quarters and missed in two, the average negative earnings surprise being 2.07%. The Zacks Consensus Estimate for revenues is currently pegged at $299.3 million for the second quarter, implying an 80.4% improvement over the year-ago period. The Zacks Consensus Estimate for the second-quarter bottom line has narrowed by 4 cents to a loss of 23 cents per share over the past 90 days. TEM's Earnings Estimate Revision Trend Image Source: Zacks Investment Research Throughout the second quarter of 2025, Tempus AI had an impressive run on the bourses with a 34.5% gain. Despite macroeconomic challenges, including escalating trade tensions that broadly impacted the healthcare technology sector, the company witnessed strong momentum, primarily driven by a series of strategic acquisitions and partnerships in the field of AI-driven precision medicine. During this period, the company not only surpassed the 9.3% gain posted by the broader industry but also significantly outperformed the 3.4% decline of the Medical sector. The S&P 500 benchmark index gained 10.7% during this period. The company has also outperformed other players in the health infotech field, like 10x Genomics TXG and SOPHiA GENETICS SOPH. While TXG gained 33.5%, SOPH declined 2.3% during the said period. Q2 Price Comparison Image Source: Zacks Investment Research Let's see how things have shaped up for TEM shares prior to this announcement: Key Factors to Note Prior to Tempus AI's Q2 Earnings Tempus AI recently announced a three-year, $200 million foundational model partnership with AstraZeneca AZN and Pathos, which is expected to have contributed to its second-quarter performance. This non-exclusive data licensing agreement aims to develop the world's largest foundation model in oncology using over 300 petabytes of Tempus' multimodal data. With the first version of the model expected in 9-12 months, the deal is already transforming Tempus AI's data monetization trajectory. Management confirmed that revenues from this deal will be recognized ratably over the three-year term, starting in the second quarter. Tempus AI's hereditary testing segment, which contributed meaningfully to first-quarter growth, is expected to have maintained the trend this time too. When Tempus acquired Ambry Genetics, it guided mid-to-high teens growth, but the segment exceeded expectations with a 23% unit increase. While management has been cautious about projecting ongoing acceleration, they have also expressed confidence in the long-term potential for broader hereditary screening applications, ranging from cancer to cardiovascular and neurological risk. Tempus continued to expand its diagnostics portfolio with the recent FDA clearance of ECG-Low EF, its second AI-powered ECG tool for detecting low ejection fraction, further strengthening its position in cardiology and extending its reach beyond oncology. Meanwhile, the company launched xM for TRM, a liquid biopsy assay for monitoring immunotherapy response, which showed promising early data at ASCO 2025. These likely contributed to the second-quarter top line too. Tempus AI is advancing its digital health strategy by integrating Tempus One, its GenAI clinical assistant, into EHR systems, enabling physicians to query data, access guidelines and streamline workflows. The launch of Agent Builder for custom GenAI tools further deepens its role in clinical settings. Tempus One too is expected to have witnessed strong customer adoption during the second quarter. However, despite strong top-line growth and product momentum, Tempus AI in 2025 is facing a few near-term challenges. The company remains unprofitable, with an adjusted EBITDA loss of $16.2 million in the first quarter. Though the loss narrowed year over year, it raised questions about the timeline to profitability amid ongoing R&D investments. Additionally, while the AstraZeneca-Pathos foundation model deal is significant, its revenues will be recognized ratably over three years, limiting short-term financial impact. Further, investments tied to these updates, including product development, regulatory efforts, and marketing, are likely to have pushed operating expenses higher in the second quarter, putting some pressure on short-term profitability. Broader macroeconomic factors, like tariffs, hospital budget constraints and biotech funding trends, could also affect adoption rates. Expensive Valuation TEM's stock is currently overvalued compared to its industry, as shown in the chart below. TEM is currently trading at a forward 12-month price-to-sales (P/S) ratio of 6.86, a premium to the broader industry's average of 5.80X. It also trades higher than other industry players like 10x Genomics (2.70X) and SOPHiA GENETICS (2.40X). However, the stock is trading below its one-year median of 8.00X, suggesting that it has moderated somewhat from its historical highs. Image Source: Zacks Investment Research Our Take With the AI market projected to grow exponentially in the coming years, Tempus AI is well-positioned to capitalize on expanding opportunities. With a strong financial outlook and efforts to improve healthcare outcomes, TEM presents a unique opportunity for investors seeking high returns from the AI and healthcare sectors. Yet, despite the company's several recent upsides, its premium valuation and lack of near-term profitability are limiting this Zacks Rank #3 (Hold) stock's near-term gains. While current shareholders should hold their positions, new investors should wait for the stock to retract some of its recent gains, providing a better entry point. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report 10x Genomics (TXG) : Free Stock Analysis Report SOPHiA GENETICS SA (SOPH) : Free Stock Analysis Report Tempus AI, Inc. (TEM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
